CX3CL1 and primary biliary cholangitis: For example, E6011 is a novel humanized anti-CX3CL1 monoclonal antibody being developed as a therapeutic target for Crohn’s disease, RA, and primary biliary cholangitis (Tabuchi et al., 2019).